• 대한조현병학회지
• /
• 제22권2호
• /
• pp.21-33
• /
• 2019

Objectives: The current study covers a secondary revision of the guidelines for the pharmacotherapy of schizophrenia issued by the Korean Medication Algorithm for Schizophrenia (KMAP-SCZ) 2001, specifically for co-existing symptoms and antipsychotics-related side-effects in schizophrenia patients. Methods: An expert consensus regarding the strategies of pharmacotherapy for positive symptoms of schizophrenia, co-existing symptoms of schizophrenia, and side-effect of antipsychotics in patients with schizophrenia was retrieved by responses obtained using a 30-item questionnaire. Results: For the co-existing symptoms, agitation could be treated with oral or intramuscular injection of benzodiazepine or antipsychotics; depressive symptoms with atypical antipsychotics and adjunctive use of antidepressant; obsessive-compulsive symptoms with selective serotonin reuptake inhibitors and antipsychotics other than clozapine and olanzapine; negative symptoms with atypical antipsychotics or antidepressants; higher risk of suicide with clozapine; comorbid substance abuse with use of naltrexone or bupropion/varenicline, respectively. For the antipsychotics-related side effects, anticholinergics (extrapyramidal symptom), propranolol and benzodiazepine (akathisia), topiramate or metformin (weight gain), change of antipsychotics to aripiprazole (hyperprolactinemia and prolonged QTc) or clozapine (tardive dyskinesia) could be used. Conclusion: Updated pharmacotherapy strategies for co-existing symptoms and antipsychotics-related side effects in schizophrenia patients as presented in KMAP-SCZ 2019 could help effective clinical decision making of psychiatrists as a preferable option.

• 대한한방내과학회지
• /
• 제27권2호
• /
• pp.546-553
• /
• 2006

Schizophrenia is a disturbance condition that lasts for at least 6 months and includes at least 1 month of active-phase symptoms(i.e., two [or more] of the following : delusions, hallucinations. disorganized speech, grossly disorganized or catatonic behavior, negative symptoms) In this study, we report one case of schizophrenia with acute cerebral infarction. The patient has been diagnosed with schizophrenia more than 20 years ago, and after this recent cerebral infarction, all of her schizophrenic symptoms such as auditory hallucination, delirium, depression, insomnia were aggravated. Her schizophrenic symptoms, PANSS and NIHSS total scores were considerably reduced after oriental treatment(Guibi-tang(歸脾湯)), so we report this as a potential treatment.

• 생물정신의학
• /
• 제4권1호
• /
• pp.95-101
• /
• 1997

The recent hypothesis about the pathophysiology of schizophrenia has been centered mainly on two theories, i.e. dopamine hypothesis and serotonin hypothesis. We investigate the correlations between plasma monoamine metabolite concentrations and clinical symptoms in schizophrenic patients. The first purpose of our study was to examine whether the plasma levels of HVA(homovanillic acid) and 5-HIAA(hydroxyindoleacetic acid) are significantly different in schizophrenics, compared to normal controls. And, with the intention of clarifying the interaction between dopaminergic system and serotoninergic system, the ratio of HVA/5-HIAA also was measured. The second purpose was whether the basal(pre-treatment) levels of these metabolites show the correlation with clinical symptoms. Finally, third purpose was whether basal HVA and 5-HIAA levels can be held as a predictor of treatment response. We used Scale for the Assessment of Positive Symptoms(SAPS) and Scale for the Assessment of Negative Symptoms(SANS) as the clinical symptom rating scales. Our results were as followed, 1) only the level of basal plasma HVA was significantly differ in schizophrenics. 5-HIAA and HVA/5-HIAA were not. 2) basal HVA showed significant correlation with SAPS score, especially delusion subscale. 3) the higher was the basal HVA level, the more improvement in clinical symptoms was observed. The basal 5-HIAA level and the HVA/5-HIAA ratio did not show any significant findings. These results support the dopamine hypothesis of schizophrenia, but fail to examine on the possible involvement of serotonin in schizophrenia.

• 한국콘텐츠학회논문지
• /
• 제11권4호
• /
• pp.458-467
• /
• 2011

본 연구는 무용/동작치료가 입원중인 정신분열증 환자의 정신건강 변화에 미치는 효과를 알아보고자 STAXI, BDI, STAI, PANSS 비교분석 하였다. 대상자는 대전 J병원에서 입원치료를 받고 있는 정신분열증 환자 중 선정기준에 적합한 38명을 무용/동작치료군 18명, 대조군 20명씩 할당하여 분노는 STAXI, 우울은 BDI, 불안은 STAI로, 양성 및 음성증상은 PANSS를 사용하여 비교분석하였다. 상태 분노가 유의하게 감소하였고, 분노 표현 중에서 분노 통제가 유의하게 증가하였다. 우울은 유의하게 감소하였으며, 음성 증후군 척도에서 유의한 호전을 보였다. 결과적으로 입원한 정신분열병 환자에게 무용/동작치료는 상태 분노를 감소시키고, 분노 통제를 증진시켰고, 우울을 감소와 음성 증상에 긍정적 효과가 나타났다.

• 생물정신의학
• /
• 제2권1호
• /
• pp.115-122
• /
• 1995

This study was performed to know the relationship between neurologic soft signs (NSS) and clinical variables such as psychopathology. history of illness, and premorbid social adjustment in patients with schizophrenia. The authors evaluated NSS in 31 patients with schizophrenia using the structured tool for measuring neurologic abnormalities, Neurological Evaluation Scale- Korean Version(NES-K). Relationships between NSS and clinical variables such as duration of illness, intensity of precipitating stressors, duration of outpatient treatment, schooling, peer relationship, total duration of unemployment, total days of psychiatric admission, age, total days of being medicated, age at the first psychiatric admission, frequency of admissions, content of treatment, social adjustment, and severity of symptoms were analyzed. Differences between paranoid and non-paranoid schizophrenics were examined. In addition, Differences between patients with schizophrenia who have predominant positive symptoms and who have predominant negative symptoms were examined too. Total scores of NES-K were correlated with lower schooling (${\gamma}$=0.44, p<0.01). Scores of motor coordination subcategory were correlated with poor peer relationship(${\gamma}$=0.67, p<0.001). Other clinical variables were not correlated with any scores of NES-K. Paranoid and non-paranoid schizophrenics were not different in scores of NES-K. Also positive and negative schizophrenics were not different in scores of NES-K. Most clinical variables except schooling and peer relationship were not related with NSS. This results indicated that the meaning of these signs was not fully be understood. Introduction of the new classification concepts such as deficit or non-deficit syndrome will be helpful to elucidate the meaning of NSS in patients with schizophrenia.

• 생물정신의학
• /
• 제25권2호
• /
• pp.31-37
• /
• 2018

Objectives The aim of this study was to evaluate the psychopathological features such as depression and anxiety in schizophrenics with obsessive-compulsive symptoms (OCS) as well as the severity of OCS according to duration of schizophrenia. Methods We randomly selected sixty four inpatients with schizophrenia. We classified the patients into two groups (OCS group, non-OCS group) according to the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Clinical and demographic features were evaluated. To assess OCS, Y-BOCS were performed. The Korean version of the Positive and Negative Syndrome Scale(K-PANSS), the Brief Psychiatric Rating Scale (BPRS), the Korean version of the Calgary Depression Scale for Schizophrenia (K-CDSS), the Beck Anxiety Inventory (BAI) and the Satisfaction With Life Scale (SWLS) were conducted. Independent t-test and chi-square test were conducted to compare the two groups. Pearson correlation analysis was performed to examine the relationship between the duration of schizophrenia and the Y-BOCS score. Results The Y-BOCS, K-CDSS, and BAI scores were higher in the OCS group. There was a significant correlation between the duration of schizophrenia and the Y-BOCS score. Conclusions Anxiety and depression symptoms were severe in the OCS group. In addition, the results of this study indicate that the longer duration of schizophrenia, the more severe the OCS. Therefore, the evaluation of OCS in schizophrenics should be accompanied by treatment intervention.

• 수면정신생리
• /
• 제11권1호
• /
• pp.44-49
• /
• 2004

목 적 : 만성 정신분열병 환자에서 양성증상과 음성증상의 호전이 인지기능에 어떤 영향을 끼치는 지를 알아보기 위함이다. 방 법：증상의 호전이 예상되는 활성기 정신분열병 환자 68명을 대상으로 입원 직후에 증상과 인지기능을 측정하고 6개월 약물치료 후 증상과 인지기능을 재차 측정하여 두 영역에서의 변화간의 연관성을 조사하였다. 또 약물치료에 의해 인지기능이 어느 수준까지 호전되는지를 알아보기 위하여 나이와 교육수준이 비슷한 정상 대조군 20명의 인지기능과도 비교하였다. 증상은 PANSS로 평가하였고, 인지기능은 고난도 지속수행검사를 이용한 지속적 주의력, 위스콘신 카드분류검사를 이용한 실행능력, 숫자 주의력을 이용한 주의 집중력, 그리고 레이 청각 언어성 학습검사를 이용한 언어성 기억과 학습 등을 측정하였다. 결 과：양성증상과 음성증상에서의 호전은 각 인지검사 점수의 변화에 유의한 영향을 미치지 않았고, 인지검사 점수의 변화에서 증상의 호전으로 설명될 수 있는 정도는 미미하였다. 또 정신분열병의 활성기에 비하여 6개월 약물치료 때의 관해기때 주의력, 실행능력, 기억력 모두 유의한 호전을 보였지만, 나이와 교육수준이 비슷한 정상대조군과 비교 시는 여전히 유의한 결손을 보였다. 결 론：이러한 결과는 정신분열병에서 증상과 인지기능이 서로 다른 영역일 가능성을 시사하며, 나아가 정신분열병 치료에 있어 증상의 호전뿐 아니라 인지기능의 호전에도 초점을 두어야 할 필요성을 부각시킨다.

• 생물정신의학
• /
• 제17권2호
• /
• pp.86-93
• /
• 2010

Objectives : The aim of this research is to determine the effects of depression and anxiety symptoms of schizophrenic psychopathology on the HPA axis. Methods : Twenty patients with schizophrenia were included and divided into the medication non-exposed group(n = 10) and the medication exposed group(n = 10). Evaluated scales were the Positive and Negative Syndrome Scale(PANSS), Scale for the Assessment of Negative Symptoms(SANS), Scale for the Assessment of Positive Symptoms(SAPS), Hamilton Depression Inventory(HAM-D) and Hamilton Anxiety Inventory (HAM-A), and then the combined Dexamethasone/Corticotropin Releasing Hormone(DEX/CRH) test was conducted to determine the basal level, the peak level and the area under the curve(AUC) of cortisol and adrenocorticotropic hormone(ACTH). Results : When the correlations between each psychopathology and cortisol level or ACTH AUC value were analyzed, HAM-D showed a negative correlation, whereas HAM-A showed a positive correlation. Also, the non-depression group(HAM-D ${\leq}$ 18) showed higher cortisol and ACTH concentrations than the depression group(HAM-D > 18), and the anxiety group(HAM-A ${\geq}$ 14) showed significantly higher concentrations than the non-anxiety group(HAM-D < 14)(p < 0.05). Also, as for the comparison between the medication non-exposed group and the medication exposed group, the non-exposed group showed significantly higher cortisol and ACTH concentration than exposed group(p < 0.05). Conclusion : This study suggest that anxiety symptoms rather than depression symptoms are related to the increased activity of the HPA axis of schizophrenics.

• 대한조현병학회지
• /
• 제23권1호
• /
• pp.29-37
• /
• 2020

Objectives: This study aimed to investigate the characteristics of early maladaptive schemas and their associations with clinical symptoms in patients with schizophrenia. Methods: Forty-eight patients with schizophrenia, 49 patients with major depressive disorder, and 50 healthy controls completed the Young Schema Questionnaire and symptom measures including the Brief Psychiatric Rating Scale-Expanded (BPRS-E). Results: The schizophrenia group had significantly higher scores than the healthy controls and lower scores than the depression group in most schemas. Compared with healthy controls, the schizophrenia group exhibited higher scores in 10 schemas, i.e., mistrust, social isolation, failure, dependence, vulnerability to harm, enmeshment, insufficient self-control, subjugation, emotional inhibition, and negativity schemas (all p<0.001). Moreover, vulnerability to harm, enmeshment, subjugation, and negativity schemas were correlated with total scores of the BPRS-E (0.37≤r≤0.43, all p<0.05). Regarding the five BPRS domains, emotional deprivation schema showed significant relationships with negative (r=0.50, p=0.005) and disorganization (r=0.39, p=0.033) symptoms, while no schemas showed correlations with positive symptoms. Conclusion: These results suggest that most schemas in patients with schizophrenia pertain to impaired autonomy and performance as well as disconnection and rejection domains and may improve our understanding and the treatment of schizophrenia from a perspective of schema therapy focused on these domains.

• 생물정신의학
• /
• 제19권4호
• /
• pp.193-198
• /
• 2012

Objectives Despite the growing research interest in the role of immunological markers in schizophrenia, a few studies, with conflicting results, have focused on the association between high sensitivity C-reactive protein (hs-CRP) levels and clinical characteristics in schizophrenia. The aim of the present study was to examine the association of serum hs-CRP with psychopathology in schizophrenia. Methods Fifty-five inpatients with schizophrenia or schizoaffective disorder were enrolled. Serum levels of hs-CRP were measured, and each patient was assessed with the Korean version of the Positive and Negative Syndrome Scale (PANSS). Results In correlation analysis of hs-CRP with PANSS subscales, positive subscale score has significant positive correlation (r = 0.271, p = 0.046). In independent t-test analysis, subjects with hs-CRP > 0.3 mg/dL (elevated CRP group, n = 43) had significantly higher PANSS positive subscale score (t = -3.273, df = 24.107, p = 0.003) than those with hs-CRP ${\leq}$ 0.3 mg/dL (normal CRP group, n = 12). Conclusions Elevated serum levels of high sensitivity C-reactive protein in schizophrenia are associated with the severity of psychotic symptoms.